Elixiron Immunotherapeutics said interim open-label Phase 2 results for enrupatinib in Alzheimer’s disease were positive, with plans to move into a biomarker-based, placebo-controlled study design. The company characterized the next step as an effort to refine patient selection and evaluate efficacy using biomarker stratification rather than an unselected clinical population. The update keeps the program on a path toward later-stage testing, contingent on ongoing data for enrupatinib’s brain-penetrant pharmacology and clinically meaningful endpoints.